Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT 3-Year EPS without NRI Growth Rate is 82.70% as of Sep. 2025, which is 48% above its 10-year median of 55.85. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Windtree Therapeutics ranks better than 96.12% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 82.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 63.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 63.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Windtree Therapeutics was 82.70% per year. The lowest was -4.50% per year. And the median was 55.85% per year.
Windtree Therapeutics (OTCPK:WINT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Windtree Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
WINT vs LIPO, ITRMF, IOBTQ: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Windtree Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Windtree Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 82.70% mean?
Windtree Therapeutics (WINT) has a 3-Year EPS without NRI Growth Rate of 82.70% as of Sep. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Windtree Therapeutics and its competitors. This is 48% above median its historical median of 55.85. According to the industry distribution chart, Windtree Therapeutics ranks #45 out of 1160 companies in the Biotechnology industry, placing it in the top 3.9%.
Is Windtree Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Windtree Therapeutics' current 3-Year EPS without NRI Growth Rate of 82.70% is 48% above median its 10-year median of 55.85. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Windtree Therapeutics' value of 82.70% is 415.3% above this industry median. Based on the distribution chart, Windtree Therapeutics ranks #45 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Windtree Therapeutics' 3-Year EPS without NRI Growth Rate compare to LIPO and ITRMF?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #45 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Windtree Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Windtree Therapeutics' value of 82.70% is 415.3% above this benchmark. While the company's 10-year median is 55.85 vs. the industry median of 16.05, Windtree Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windtree Therapeutics's current 3-Year EPS without NRI Growth Rate of 82.70% is 415.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Windtree Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current 3-Year EPS without NRI Growth Rate is 82.70%, which is 48% above median its own 10-year median of 55.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current 3-Year EPS without NRI Growth Rate of 82.70%. The current 3-Year EPS without NRI Growth Rate is 82.70%, which is 48% above median its 10-year median of 55.85 and 415.3% above the Biotechnology industry median of 16.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current 3-Year EPS without NRI Growth Rate is 82.70% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
